Effectiveness of treatment of an elderly patient with good prognosis of multiple myeloma
Abstract
Background: Case report presents the treatment of a multiple myeloma patient with different schemes used in Slovenia in the last 10 years, the inclusion of different medicines in treatment protocols and the evaluation of their effectiveness. Patient and treatment: This 79-year old patient had multiple myeloma IgA lambda with good disease prognosis diagnosed in July 2001 at the age of 69 years. Considering his age > 65 years at the time of diagnosis, patient was not suitable for autologous transplantation and was treated with different treatment schemes: MP (melphalan, prednisone), TM (thalidomide, methylprednisolone), VAD (vincristine, doxorubicine substituted by farmorubicin, dexamethasone), As2O3D (arsenic trioxide, dexamethasone), Vel (bortezomib), VelD (bortezomib, dexamethasone), Ciklo (cyclophosphamide), LenM (lenalidomide, methylprednisolone), Melfiv (melphalan iv), VelDvzdr (bortezomib and dexamethasone, maintenance every 14 days). Results: Treatment effectiveness was evaluated according to modified SWOG criteria. Patient responded to the first Vel treatment with CR that was maintained for 19 months. With the second VelD, VGPR was achieved and maintained for 10 months, and after the third VelD, the response was maintained for 6 months until subsequent therapy. Patient responded to the fourth VelD with MR. Since the patient is not responsive to previously used treatments, in last 5 months he is receiving VelDvzdr and in this period mIgA value increased by less than 5 g/L. Treatment with MP resulted in MR, with Melfiv and As2O3D we achieved SD, while treatments with VAD, Ciklo, TM and LenM were ineffective. Peripheral neuropathy as an important side effect developed after 3 cycles of the first Vel treatment and was resolved in the subsequent cycles. Conclusions: In older patients with good disease prognosis, treated with older treatment schemes, the expected median survival was few years. After 43 months of treatment with older treatment schemes our patient became refractory and was subsequently treated with new medicines. With bortezomib as the only effective medicine, his disease went through different stages, and he survived another 72 months with good quality of life.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
